Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease

Table 2 Correlation between hepatic steatosis and cardiovascular risk by the Framingham system (n = 69)

	Steatosis (CAP), n (%)
	S0, n = 13	S1, n = 7	S2, n = 3	S3, n = 46	P value
Framingham
Mild (n = 18)	3 (4.3)	2 (2.9)	0	13 (18.8)	0.254
Moderate (n = 24)	5 (7.2)	5 (7.2)	1 (1.4)	13 (18.8)
High (n =27)	5 (7.2)	0	2 (2.9)	20 (28.9)

Degree of steatosis due to controlled attenuation parameter: S0 < 5% of hepatic fatty tissue, S1 between 5% to 33%, S2 between 34% to 66% and S3 > 64%. Cap: controlled attenuation parameter.